{
  "abstract": "Importance: Since liraglutide's approval for the treatment of type 2 diabetes (T2D) in children, no real-world studies have examined its clinical outcomes in adolescents.\n\nObjective: Compare hemoglobin A1c (HbA1c) changes in adolescents with T2D taking liraglutide in a clinical setting.\n\nDesign: Retrospective cohort study from 2020 to 2023.\n\nParticipants: Patients with T2D ages <18 years who were prescribed liraglutide. Patients were divided into 2 groups: treated (those with evidence of taking liraglutide for ≥26 weeks) and control (those prescribed but who did not take liraglutide).\n\nMain outcomes: Changes in HbA1c after 26 weeks of treatment were calculated. Secondary outcomes included HbA1c changes after 52 weeks, and body mass index (BMI) z score changes and lipid markers at 26 and/or 52 weeks.\n\nResults: There was a strong trend toward a decrease in HbA1c after 26 weeks of liraglutide treatment compared with control (−0.40 [−1.90, 0.20] vs +0.15 [−1.30, 0.88], P = .064; n = 85 vs n = 30); no difference was observed at 52 weeks (−0.20 [−1.23,0.93] vs 0.50 [−1.13,1.70], P = .15; n = 100 vs n = 44). BMI z score was stable in both groups, with no differences between groups. Lipid levels were available in a small subset of patients. The liraglutide-treated group had a decrease in total cholesterol (−0.21 [−0.60, 0.16] mmol/L vs 0.49 [0.06, 0.76] mmol/L, P = .005; n = 36 vs n = 12) and low-density lipoprotein (−0.23 [−0.56, 0.16] mmol/L vs 0.35 [0.14, 0.63] mmol/L, P < .01; n = 31 vs n = 12) vs control.\n\nConclusion: Liraglutide shows potential benefits for lowering HbA1c and cholesterol in children with T2D in a clinical setting. Additional work is needed to understand how to optimize HbA1c improvements with liraglutide.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "name": "Gabriel Castano Heredia",
      "orcid": "0000-0002-4217-8451"
    },
    {
      "name": "Rebecca Schneider Aguirre",
      "orcid": "0000-0001-7279-9470"
    },
    {
      "name": "Jennifer Bell"
    },
    {
      "name": "Selorm Dei-Tutu"
    },
    {
      "name": "Xioafan Huang",
      "orcid": "0000-0002-9337-9456"
    },
    {
      "name": "Danielle Guffei",
      "orcid": "0000-0003-3721-614X"
    },
    {
      "name": "Serife Uysal-Demiroz"
    },
    {
      "name": "Siripoom McKay",
      "orcid": "0000-0002-4387-0191"
    },
    {
      "name": "Nidhi Bansal",
      "orcid": "0009-0009-8487-2941"
    },
    {
      "name": "Stephanie Sisley",
      "orcid": "0000-0003-2900-7014"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/bpa63vabqskt9.bib",
  "cited_by": 0,
  "doi": "10.1210/jendso/bvag230",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13696829/",
  "id": "bpa63vabqskt9",
  "issns": [
    "2472-1972"
  ],
  "landing_url": "https://doi.org/10.1210/jendso/bvag230",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "AcademicSubjects/MED00250"
    ],
    [
      "heading",
      "Clinical Research Article"
    ],
    [
      "heading",
      "Jes/4"
    ],
    [
      "openalex",
      "2712|Diabetes Treatment and Management"
    ]
  ],
  "openalex": "W7220694531",
  "pdf_url": "https://europepmc.org/articles/PMC13696829?pdf=render",
  "pmcid": "PMC13696829",
  "pmid": "42936196",
  "published": "2026-10-05",
  "publisher": "The Endocrine Society",
  "ris": "https://research.draconitic.com/paper/bpa63vabqskt9.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:07Z",
      "native_id": "PMC13696829",
      "source": "pmc",
      "url": "https://doi.org/10.1210/jendso/bvag230"
    },
    {
      "first_seen": "2026-10-30T12:22:24Z",
      "native_id": "MED:42936196",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42936196"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2712|Diabetes Treatment and Management",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Real-world effectiveness of liraglutide in children with type 2 diabetes",
  "title_text": "Real-world effectiveness of liraglutide in children with type 2 diabetes",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:34:06Z",
  "url": "https://research.draconitic.com/paper/bpa63vabqskt9",
  "venue": "Journal of the Endocrine Society",
  "versions": []
}